Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
- Conditions
- Interventions
- Biological: aldesleukinBiological: filgrastimBiological: recombinant interferon gammaDrug: carmustineDrug: cyclosporineDrug: cytarabineDrug: etoposideDrug: melphalanProcedure: autologous bone marrow transplantationProcedure: bone marrow ablation with stem cell supportProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2013-10-17
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 24
- Registration Number
- NCT00070187
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Minnesota - Minneapolis, Minneapolis, Minnesota, United States
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00070551
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2003-09-25
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- ALZA
- Target Recruit Count
- 25
- Registration Number
- NCT00003827
- Locations
- 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 30
- Registration Number
- NCT00002638
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2003-09-03
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT00006265
- Locations
- 🇺🇸
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States
🇺🇸Veterans Affairs Medical Center - Dallas, Dallas, Texas, United States
🇺🇸CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States
506U78 in Treating Patients With Refractory Hematologic Cancer
- First Posted Date
- 2003-08-11
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 148
- Registration Number
- NCT00002970
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 69
- Registration Number
- NCT00066794
- Locations
- 🇺🇸
St. Luke's Mountain States Tumor Institute - Boise, Boise, Idaho, United States
🇺🇸Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States
🇺🇸Munson Medical Center, Traverse City, Michigan, United States
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2003-07-18
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00065143
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
- Conditions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Registration Number
- NCT00064090
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇪🇬National Cancer Institute of Egypt, Cairo, Egypt
🇮🇳Kidwai Memorial Institute of Oncology, Bangalore, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.